SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-003998
Filing Date
2024-06-05
Accepted
2024-06-05 17:00:14
Documents
18
Period of Report
2024-06-03
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm   iXBRL 8-K 54275
2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION O cns_ex0301.htm EX-3.1 4622
3 PRESS RELEASE cns_ex9901.htm EX-99.1 7435
7 GRAPHIC image_003.jpg GRAPHIC 944017
8 GRAPHIC image_004.jpg GRAPHIC 901846
9 GRAPHIC image_005.jpg GRAPHIC 4730
  Complete submission text file 0001683168-24-003998.txt   2800629

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cnsp-20240603.xsd EX-101.SCH 3018
5 XBRL LABEL FILE cnsp-20240603_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE cnsp-20240603_pre.xml EX-101.PRE 22361
21 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3919
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 241022807
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)